Key points are not available for this paper at this time.
The landscape of cancer treatment has undergone a vast change over the past four decades 1,2. Discovery of the heterogeneous molecular features of tumors and the associated microenvironment has led to the development of novel classes of targeted therapeutics 3–5, the two main types of which are small-molecule inhibitors and monoclonal antibodies (mAbs) 1–3. These targeted drugs have furthered the development of personalized therapeutic regimens in oncology.
Kang et al. (Fri,) studied this question.